Summary | |
---|---|
Symbol | SCYL2 |
Name | SCY1-like, kinase-like 2 |
Aliases | KIAA1360; CVAK104; coated vesicle-associated kinase of 104 kDa; SCY1-like 2 (S. cerevisiae); SCY1-like 2; SC ...... |
Chromosomal Location | 12q23.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cytoplasm, perinuclear region. Cytoplasmic vesicle, clathrin-coated vesicle. Golgi apparatus, trans-Golgi network membrane. Endosome membrane. Note=According to PubMed:15809293, plasma membrane-associated in clathrin-coated vesicles. According to PubMed:16914521, colocalizes to the trans-Golgi network (TGN) and to endosomal membranes with clathrin, transferrin and plasma membrane adapter AP1 and AP3 complexes. |
Domain |
PF00069 Protein kinase domain |
Function |
Component of AP2-containing clathrin coated structures at the plasma membrane or of endocytic coated vesicles. According to PubMed:15809293, probable serine/threonine-protein kinase that phosphorylates, in vitro, the beta2-subunit of the plasma membrane adapter complex AP2 and other proteins in presence of poly-L-lysine. According to PubMed:16914521, has no detectable kinase activity in vitro. May regulate clathrin-dependent trafficking between the TGN and/or the endosomal system. |
Biological Process |
GO:0002090 regulation of receptor internalization GO:0002092 positive regulation of receptor internalization GO:0006898 receptor-mediated endocytosis GO:0007034 vacuolar transport GO:0007041 lysosomal transport GO:0008333 endosome to lysosome transport GO:0016055 Wnt signaling pathway GO:0016197 endosomal transport GO:0030100 regulation of endocytosis GO:0030111 regulation of Wnt signaling pathway GO:0030178 negative regulation of Wnt signaling pathway GO:0031623 receptor internalization GO:0043112 receptor metabolic process GO:0045807 positive regulation of endocytosis GO:0048259 regulation of receptor-mediated endocytosis GO:0048260 positive regulation of receptor-mediated endocytosis GO:0060070 canonical Wnt signaling pathway GO:0060627 regulation of vesicle-mediated transport GO:0060828 regulation of canonical Wnt signaling pathway GO:0072583 clathrin-dependent endocytosis GO:0090090 negative regulation of canonical Wnt signaling pathway GO:0198738 cell-cell signaling by wnt GO:2000286 receptor internalization involved in canonical Wnt signaling pathway GO:2000369 regulation of clathrin-dependent endocytosis GO:2000370 positive regulation of clathrin-dependent endocytosis |
Molecular Function | - |
Cellular Component |
GO:0010008 endosome membrane GO:0030135 coated vesicle GO:0030136 clathrin-coated vesicle GO:0044440 endosomal part |
KEGG | - |
Reactome | - |
Summary | |
---|---|
Symbol | SCYL2 |
Name | SCY1-like, kinase-like 2 |
Aliases | KIAA1360; CVAK104; coated vesicle-associated kinase of 104 kDa; SCY1-like 2 (S. cerevisiae); SCY1-like 2; SC ...... |
Chromosomal Location | 12q23.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between SCYL2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | SCYL2 |
Name | SCY1-like, kinase-like 2 |
Aliases | KIAA1360; CVAK104; coated vesicle-associated kinase of 104 kDa; SCY1-like 2 (S. cerevisiae); SCY1-like 2; SC ...... |
Chromosomal Location | 12q23.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of SCYL2 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | SCYL2 |
Name | SCY1-like, kinase-like 2 |
Aliases | KIAA1360; CVAK104; coated vesicle-associated kinase of 104 kDa; SCY1-like 2 (S. cerevisiae); SCY1-like 2; SC ...... |
Chromosomal Location | 12q23.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of SCYL2 in various data sets.
|
Points in the above scatter plot represent the mutation difference of SCYL2 in various data sets.
|
Summary | |
---|---|
Symbol | SCYL2 |
Name | SCY1-like, kinase-like 2 |
Aliases | KIAA1360; CVAK104; coated vesicle-associated kinase of 104 kDa; SCY1-like 2 (S. cerevisiae); SCY1-like 2; SC ...... |
Chromosomal Location | 12q23.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SCYL2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | SCYL2 |
Name | SCY1-like, kinase-like 2 |
Aliases | KIAA1360; CVAK104; coated vesicle-associated kinase of 104 kDa; SCY1-like 2 (S. cerevisiae); SCY1-like 2; SC ...... |
Chromosomal Location | 12q23.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SCYL2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SCYL2. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | SCYL2 |
Name | SCY1-like, kinase-like 2 |
Aliases | KIAA1360; CVAK104; coated vesicle-associated kinase of 104 kDa; SCY1-like 2 (S. cerevisiae); SCY1-like 2; SC ...... |
Chromosomal Location | 12q23.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SCYL2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | SCYL2 |
Name | SCY1-like, kinase-like 2 |
Aliases | KIAA1360; CVAK104; coated vesicle-associated kinase of 104 kDa; SCY1-like 2 (S. cerevisiae); SCY1-like 2; SC ...... |
Chromosomal Location | 12q23.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of SCYL2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | SCYL2 |
Name | SCY1-like, kinase-like 2 |
Aliases | KIAA1360; CVAK104; coated vesicle-associated kinase of 104 kDa; SCY1-like 2 (S. cerevisiae); SCY1-like 2; SC ...... |
Chromosomal Location | 12q23.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between SCYL2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | SCYL2 |
Name | SCY1-like, kinase-like 2 |
Aliases | KIAA1360; CVAK104; coated vesicle-associated kinase of 104 kDa; SCY1-like 2 (S. cerevisiae); SCY1-like 2; SC ...... |
Chromosomal Location | 12q23.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting SCYL2 collected from DrugBank database. |
There is no record. |